PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN)
PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: PLUVICTO; Generic name: LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN; Drug class: Radioligand Therapeutic Agent [EPC].
| Brand name | PLUVICTO |
|---|---|
| Generic name | LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN |
| Drug class | Radioligand Therapeutic Agent [EPC] |
| Manufacturer | Novartis Pharmaceuticals Corporation |
| Used for | 1 INDICATIONS AND USAGE PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy, and are considered appropriate to delay taxane-based chemotherapy, or have received prior taxane-based chemotherapy. PLUVICTO is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy, and are considered appropriat |
| Dosage | 2 DOSAGE AND ADMINISTRATION Select patients for treatment using LOCAMETZ ® or another approved PSMA positron emission tomography (PET) product based on PSMA expression in tumors. ( 2.2 ) Recommended Dosage: Administer 7.4 GBq (200 mCi) every 6 weeks for 6 doses. ( 2.3 ) Dose interruption, reduction, or permanent discontinuation may be required due to adverse reactions. ( 2.4 ) 2.1 Important Safety Instructions PLUVICTO is a radiopharmaceutical; handle with appropriate safety measures to minimize |
| Active ingredient(s) | LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a |